JNNP podcast
Summary: From June 2023, all our podcasts will move to https://jnnpbmj.podbean.com. You can continue with your subscription on your favourite podcast App. JNNP's ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
- Visit Website
- RSS
- Artist: BMJ Group
- Copyright: 643134
Podcasts:
Atherosclerosis is a major contributor to increased risk of stroke. Our patient’s choice, Professor Peter Kelly (University College Dublin, Dublin, Ireland) discusses the evidence base implicating inflammation as a key process in the pathogenesis of atherosclerosis, leading to thromboembolic events. Read the full paper here: http://jnnp.bmj.com/content/89/2/211. How do you measure disease progression in a highly variable and heterogeneous clinical population, such as amyotrophic lateral sclerosis (ALS)? Can plasma creatinine act as a robust surrogate biomarker in clinical trials? Dr. Ruben P A van Eijk (University Medical Center, Utrecht, The Netherlands) discusses this month’s editor’s choice. Read the full paper here: http://jnnp.bmj.com/content/89/2/156.
People with multiple sclerosis (MS) use complementary and alternative treatments (CAM), but what does the evidence say? Patient’s Choice, Professor Bruce Taylor (University of Tasmania) discusses the modern evidence for CAM use. Read the paper here: http://jnnp.bmj.com/content/89/1/34. What roles do nodes and paranodes play in complex neuropathies? Dr Simon Rinaldi (University of Oxford) summarises the involvement of these specialised domains as this month’s Editor’s Choice. Read the full paper here: http://jnnp.bmj.com/content/89/1/61. Read the JNNP's January 2018 issue here: http://jnnp.bmj.com/content/89/1.
People with multiple sclerosis (MS) use complementary and alternative treatments (CAM), but what does the evidence say? Patient’s Choice, Professor Bruce Taylor (University of Tasmania) discusses the modern evidence for CAM use. Read the paper here: http://jnnp.bmj.com/content/89/1/34. What roles do nodes and paranodes play in complex neuropathies? Dr Simon Rinaldi (University of Oxford) summarises the involvement of these specialised domains as this month’s Editor’s Choice. Read the full paper here: http://jnnp.bmj.com/content/89/1/61. Read the JNNP's January 2018 issue here: http://jnnp.bmj.com/content/89/1.
Despite the prevalence of the disease, neurologists and psychiatrists can be wary of treating patients with functional neurological disorder (FND). Assistant Professor David Perez (Massachusetts General Hospital, USA) discusses how FND sits between neurological and psychiatric disciplines, the relationship between poor health status and affective symptoms, and associations with grey matter volumetric profiles. Read more here: http://jnnp.bmj.com/content/88/12/1052.
Despite the prevalence of the disease, neurologists and psychiatrists can be wary of treating patients with functional neurological disorder (FND). Assistant Professor David Perez (Massachusetts General Hospital, USA) discusses how FND sits between neurological and psychiatric disciplines, the relationship between poor health status and affective symptoms, and associations with grey matter volumetric profiles. Read more here: http://jnnp.bmj.com/content/88/12/1052.
Is methamphetamine use linked to strokes in young adults? Important clinical implications discussed by Dr. Julia Lappin (University of New South Wales) in this month’s JNNP podcast. http://jnnp.bmj.com/content/88/12/1079
Is methamphetamine use linked to strokes in young adults? Important clinical implications discussed by Dr. Julia Lappin (University of New South Wales) in this month’s JNNP podcast. http://jnnp.bmj.com/content/88/12/1079
Cerebral amyloid angiopathy (CAA) has been gaining attention over the past few years, thanks to increased research in the field. Professor David Werring (UCL Institute of Neurology, Queens Square, London) discusses the recent advances in biomarkers analysis, as well as providing an overview of the clinical spectrum of CAA. Read the full paper here: http://jnnp.bmj.com/content/early/2017/08/26/jnnp-2016-314697
Cerebral amyloid angiopathy (CAA) has been gaining attention over the past few years, thanks to increased research in the field. Professor David Werring (UCL Institute of Neurology, Queens Square, London) discusses the recent advances in biomarkers analysis, as well as providing an overview of the clinical spectrum of CAA. Read the full paper here: http://jnnp.bmj.com/content/early/2017/08/26/jnnp-2016-314697
Professor Emeritus Andrew Eisen (University of British Columbia, Canada) discusses the theory of corticofugal primary in amyotrophic lateral sclerosis. ALS can be viewed as a primarily human disorder mediated by corticomotorneuronal pathways, originating in the cerebral cortex. Read the full paper here: http://jnnp.bmj.com/content/88/11/917.
Professor Emeritus Andrew Eisen (University of British Columbia, Canada) discusses the theory of corticofugal primary in amyotrophic lateral sclerosis. ALS can be viewed as a primarily human disorder mediated by corticomotorneuronal pathways, originating in the cerebral cortex. Read the full paper here: http://jnnp.bmj.com/content/88/11/917.
Can IViG be used as a longer term maintenance therapy for CIDP patients? JNNP Associate Editor, Professor Satoshi Kuwabara (Chiba University Hospital, Japan) joins us for this podcast, discussing recent trial results and their implications for patient care. Read the full paper here: http://jnnp.bmj.com/content/88/10/832
Can IViG be used as a longer term maintenance therapy for CIDP patients? JNNP Associate Editor, Professor Satoshi Kuwabara (Chiba University Hospital, Japan) joins us for this podcast, discussing recent trial results and their implications for patient care. Read the full paper here: http://jnnp.bmj.com/content/88/10/832
Professor Mary Reilly (Institute of Neurology, Queens Square, London) discusses how complex inherited neuropathies can be a daunting diagnosis for clinicians. However, through exciting advances in next generation sequencing and knowledge of distinct syndromic categories, a new diagnostic approach emerges. Her review and her interview provide excellent over of this new approach, and how it may serve as a resource for clinicians. Link to paper here: http://dx.doi.org/10.1136/jnnp-2016-313960.
Professor Mary Reilly (Institute of Neurology, Queens Square, London) discusses how complex inherited neuropathies can be a daunting diagnosis for clinicians. However, through exciting advances in next generation sequencing and knowledge of distinct syndromic categories, a new diagnostic approach emerges. Her review and her interview provide excellent over of this new approach, and how it may serve as a resource for clinicians. Link to paper here: http://dx.doi.org/10.1136/jnnp-2016-313960.
